Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab OzogamicinMichele Gottardi, Giovanni Martinelli, Andrea Ghelli Luserna di Rorà et al.|Cancers|2021Cited by 19
A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trialChiara Sartor, Antonio Curti, Anna Candoni et al.|Blood|2025Cited by 0